DE60310736D1 - Collectin-komplement aktivierende proteinchimären - Google Patents

Collectin-komplement aktivierende proteinchimären

Info

Publication number
DE60310736D1
DE60310736D1 DE60310736T DE60310736T DE60310736D1 DE 60310736 D1 DE60310736 D1 DE 60310736D1 DE 60310736 T DE60310736 T DE 60310736T DE 60310736 T DE60310736 T DE 60310736T DE 60310736 D1 DE60310736 D1 DE 60310736D1
Authority
DE
Germany
Prior art keywords
fusion protein
collectin
complement
activating
activating protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60310736T
Other languages
English (en)
Other versions
DE60310736T2 (de
Inventor
Leif Kongerslev
Dietmar Weilguny
Finn Matthiesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natlmmune AS
Original Assignee
Natlmmune AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natlmmune AS filed Critical Natlmmune AS
Publication of DE60310736D1 publication Critical patent/DE60310736D1/de
Application granted granted Critical
Publication of DE60310736T2 publication Critical patent/DE60310736T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60310736T 2002-09-10 2003-09-10 Collectin-komplement aktivierende proteinchimären Expired - Fee Related DE60310736T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200201328 2002-09-10
DKPA200201328 2002-09-10
PCT/DK2003/000585 WO2004024925A2 (en) 2002-09-10 2003-09-10 Collectin-complement activating protein chimeras

Publications (2)

Publication Number Publication Date
DE60310736D1 true DE60310736D1 (de) 2007-02-08
DE60310736T2 DE60310736T2 (de) 2007-10-11

Family

ID=31984965

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60310736T Expired - Fee Related DE60310736T2 (de) 2002-09-10 2003-09-10 Collectin-komplement aktivierende proteinchimären

Country Status (11)

Country Link
US (1) US20060188963A1 (de)
EP (1) EP1539964B1 (de)
JP (1) JP2005537807A (de)
CN (1) CN1694961A (de)
AT (1) ATE349538T1 (de)
AU (1) AU2003260286A1 (de)
DE (1) DE60310736T2 (de)
DK (1) DK1539964T3 (de)
ES (1) ES2279981T3 (de)
PT (1) PT1539964E (de)
WO (1) WO2004024925A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0522113D0 (en) * 2005-10-28 2005-12-07 Ares Trading Sa vWFA-domain containing proteins
CA2963124C (en) 2007-07-10 2019-10-15 Apogenix Ag Tnf superfamily collectin fusion proteins
EP2225269A2 (de) * 2007-11-09 2010-09-08 Anaphore, Inc. Fusionsproteine von mannosebindenden lektinen zur behandlung von krankheiten
US20100331240A1 (en) * 2008-01-18 2010-12-30 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
US8470555B2 (en) * 2008-12-22 2013-06-25 National University Corporation Hokkaido University Protein substance having triple helix structure and manufacturing method therefor
WO2010078966A1 (en) * 2009-01-09 2010-07-15 Apogenix Gmbh Fusion proteins forming trimers
EP2392352B1 (de) * 2009-01-28 2017-10-25 Korea Research Institute of Bioscience and Biotechnology Cd93 bzw. verwendung eines löslichen fragments davon
WO2011006982A2 (en) * 2009-07-17 2011-01-20 Rigshospitalet Inhibitors of complement activation
CN102947341B (zh) 2010-01-19 2018-07-06 哈佛大学校长及研究员协会 用于病原体检测和治疗的工程化调理素
KR20120135405A (ko) * 2010-03-04 2012-12-13 후소 야쿠힝 고교 가부시끼가이샤 허혈성 질환 항진 작용을 갖는 폴리펩티드
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
CA2842321C (en) 2011-07-18 2022-05-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
EP2820147B1 (de) 2012-02-29 2018-08-08 President and Fellows of Harvard College Schnelltests auf empfindlichkeit gegen antibiotika
EP2976642A4 (de) 2013-03-15 2016-09-21 Harvard College Verfahren und zusammensetzungen zur verbesserung der erkennung und/oder aufnahme einer zieleinheit
EP3010522B1 (de) 2013-05-21 2021-01-20 President and Fellows of Harvard College Manipulierte hemebindende zusammensetzungen und verwendungen davon
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
JP2014218510A (ja) * 2014-08-11 2014-11-20 アポゲニクスゲゼルシャフト ミット ベシュレンクテルハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
JP2016210791A (ja) * 2016-08-03 2016-12-15 アポゲニクス アーゲー 三量体形成融合タンパク質
SG10201802979VA (en) * 2018-04-10 2019-11-28 Kah Meng Lim Immunological extract and method of production
WO2022079308A1 (en) * 2020-10-16 2022-04-21 Institut Pasteur Chimeric constructs useful in vaccination and cancer therapy
CN113307857B (zh) * 2021-01-14 2022-11-01 艾时斌 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白
AU2022361048A1 (en) * 2021-10-07 2024-05-02 Omeros Corporation Targeted catalytic complement-activating molecules and methods of use thereof
CN114344453A (zh) * 2022-01-18 2022-04-15 华南师范大学 一种罗非鱼cl-k1在制备预防和/或治疗罗非鱼病害的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1008351B1 (de) * 1997-08-21 2006-11-15 Takara Bio Inc. Karzinostatische wirkstoffe
US7049099B2 (en) * 1998-01-23 2006-05-23 Fuso Pharmaceutical Industries, Ltd. Recombinant human mannan-binding proteins and producing method of the same
JPH11206378A (ja) * 1998-01-23 1999-08-03 Fuso Pharmaceutical Industries Ltd 組換えヒトマンナン結合タンパク質およびその製造方法
US6337193B1 (en) * 1998-11-24 2002-01-08 Aptagen, Inc. Expression of manose-binding protein in methylotrophic yeast
PT1402897E (pt) * 1999-05-14 2007-01-31 Jens Christian Jensenius Novas indicações de lectina de ligação a manana (mbl) no tratamento de indivíduos imunocomprometidos
US20030186419A1 (en) * 1999-12-02 2003-10-02 Jensenius Jens Christian Masp-3, a complement-fixing enzyme, and uses for it
DK1303591T3 (da) * 2000-07-13 2009-11-02 Helion Biotech Aps MASP-2, et komplementfikserende enzym, og anvendelser af det
US20050137126A1 (en) * 2003-04-09 2005-06-23 Natlmmune A/S Treatment of SARS in individuals

Also Published As

Publication number Publication date
EP1539964B1 (de) 2006-12-27
ES2279981T3 (es) 2007-09-01
CN1694961A (zh) 2005-11-09
WO2004024925A2 (en) 2004-03-25
US20060188963A1 (en) 2006-08-24
ATE349538T1 (de) 2007-01-15
AU2003260286A1 (en) 2004-04-30
DK1539964T3 (da) 2007-05-07
WO2004024925A8 (en) 2004-05-21
JP2005537807A (ja) 2005-12-15
DE60310736T2 (de) 2007-10-11
EP1539964A2 (de) 2005-06-15
WO2004024925A3 (en) 2004-06-24
PT1539964E (pt) 2007-04-30

Similar Documents

Publication Publication Date Title
DE60310736D1 (de) Collectin-komplement aktivierende proteinchimären
ATE427116T1 (de) Behandlung von bakteriellen infektionen
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
DE69412243T2 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
DE602004011770D1 (de) Fusionsproteine
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
KR950702248A (ko) 단백질을 기초로 한 전달 시스템(protein based delivery system)
DE69410254T2 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
DE60333868D1 (de) Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
ATE427320T1 (de) Behandlung von infektionen verursacht von mikroorganismen
DE69840024D1 (de) Antimikrobielle Peptide, abstammend von Ubiquicidin
ATE373091T1 (de) Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
DE69131355T2 (de) Die knochenresorption hemmende verbindungen und zusammensetzungen
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
NO945031D0 (no) Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner
BR0012740A (pt) Compostos para tratamento de distúrbios do sistema infeccioso e imune e métodos para seu emprego
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
DE69421705T2 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
MX9800686A (es) Nueva proteina hmw humana mp52s.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee